← Back to headlines
Celularity Finalizes Strategic License Deal for Biomaterials Portfolio
Celularity has successfully secured a strategic license deal for its biomaterials portfolio, with the agreement potentially valued at up to $35 million.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
